ESR 15: Angela Effinger
Developing in vitro and in silico approaches to predict the impact of Gastrointestinal Disease states on drug product performance

PEARRL research
Angela will develop clinical relevant dissolution methodology for patients with gastrointestinal diseases. In addition, she will develop an absorption model for gastrointestinal diseases that takes into account differing physiological conditions. Based on comparison with in vivo data, she will further evaluate the in vitro and in silico models.

Host
University of Bath, Department of Pharmacy and Pharmacology

Supervisory Team
Dr. N. Fotaki (UBAH), Prof. C. O’Driscoll (UCC), Dr. M. McAllister (Pfizer)

Scientific Background
Angela studied pharmacy at the Albert-Ludwigs-University of Freiburg, Germany. After her basic studies she did an Erasmus Placement internship in the department of pharmaceutical technology at the University of Montpellier 1, France, where she worked with polyionic-complex micelles for the delivery of siRNA. During an internship in the department of Formulation Research & Development at Hoffmann-La Roche AG, Basel, Switzerland, she worked on a pediatric oral suspension formulation and gained insight into the formulation development of small molecules.
Peer Reviewed Journal Articles
  • Chara Litou C., Effinger A., Kostewicz E.S., Box K.J., Fotaki N., Dressman J.B. (2018). Effects of medicines used to treat gastrointestinal diseases on the pharmacokinetics of coadministered drugs: a PEARRL Review. Journal of Pharmacy and Pharmacology. https://doi.org/10.1111/jphp.12983
  • Effinger, A., O'Driscoll, C. M. O. D., McAllister, M., & Fotaki, N. (2018). Impact of Gastrointestinal Disease States on Oral Drug Absorption – implications for formulation design – a PEARRL review. Journal of Pharmacy and Pharmacology. DOI: 10.1111/jphp.12928
Contact
a.effinger [at] bath [dot] ac [dot] uk